Expression and Diagnostic Evaluation of the Human Tumor–Associated Antigen RCAS1 in Pancreatic Cancer
暂无分享,去创建一个
H. Nawata | M. Nakashima | Tetsuhide Ito | Takeshi Watanabe | K. Nishiyama | Y. Arita | Toshinari Kimura | Tetsuro Akashi | T. Sumii | Hideki Oimomi
[1] K. Sugimachi,et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. , 2001, Cancer letters.
[2] Hidetoshi Takahashi,et al. RCAS1 antigen is highly expressed in extramammary Paget's disease and in advanced stage squamous cell carcinoma of the skin. , 2001, Journal of dermatological science.
[3] J. Sahel,et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: Report of a case series and review of the literature , 2001, American Journal of Gastroenterology.
[4] S. Hirohashi,et al. Invasive carcinoma derived from intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic and immunohistochemical study of eight cases , 2001, Virchows Archiv.
[5] H. Kitagawa,et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. , 2001, International journal of oncology.
[6] H. Kuwano,et al. Circulating soluble Fas ligand in patients with gastric carcinoma , 2000, Cancer.
[7] M. Nakashima,et al. Expression and prognostic significance in lung cancer of human tumor‐associated antigen RCAS1 , 2000, International journal of cancer.
[8] T. Chiba,et al. Clinical analysis of autoimmune-related pancreatitis , 2000, American Journal of Gastroenterology.
[9] U. Rodeck,et al. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] M. Tempero,et al. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. , 1999, Gastroenterology.
[11] Higashi,et al. Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings , 1999, Clinical nuclear medicine.
[12] K. Okumura,et al. The alteration of fas receptor and ligand system in hepatocellular carcinomas: How do hepatoma cells escape from the host immune surveillance in vivo? , 1999, Hepatology.
[13] M. Nakashima,et al. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 , 1999, Nature Medicine.
[14] S. Shott,et al. Immunoregulation in pancreatic cancer patients , 1999, Cancer Immunology, Immunotherapy.
[15] T. Murayama,et al. Levels of soluble FasL and FasL gene expression during the development of graft‐versus‐host disease in DLT‐treated patients , 1999, British journal of haematology.
[16] K. Ohshima,et al. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders , 1998, British journal of haematology.
[17] Y. Yazaki,et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease , 1998, Bone Marrow Transplantation.
[18] T. Kaku,et al. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] M. Duffy. CA 19-9 as a Marker for Gastrointestinal Cancers: A Review , 1998, Annals of clinical biochemistry.
[20] J. Devière,et al. Intraductal papillary and mucinous tumors of the pancreas: accuracy of preoperative computed tomography, endoscopic retrograde pancreatography and endoscopic ultrasonography, and long-term outcome in a large surgical series. , 1998, Gastrointestinal endoscopy.
[21] D. Gouma,et al. Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. , 1997, Gastrointestinal endoscopy.
[22] James D. Evans,et al. Chronic pancreatitis and pancreatic carcinoma. , 1997, Postgraduate medical journal.
[23] K. Isselbacher,et al. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] D. Green,et al. Human lung carcinomas express Fas ligand. , 1997, Cancer research.
[25] P. Galle,et al. Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion? , 1996, Nature Medicine.
[26] J. Tschopp,et al. Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.
[27] L. Owen-Schaub,et al. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. , 1996, Cancer research.
[28] F. Shanahan,et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand , 1996, The Journal of experimental medicine.
[29] M. Makuuchi,et al. Duct-ectatic type of mucin producing tumor of the pancreas--new concept of pancreatic neoplasia. , 1996, Hepato-gastroenterology.
[30] T. Kaku,et al. A novel tumor‐associated antigen expressed in human uterine and ovarian carcinomas , 1996, Cancer.
[31] D. L. Sobin,et al. Histological Typing of Tumours of the Exocrine Pancreas , 1996, World Health Organization International Histological Classification of Tumours.
[32] K. Yoshino,et al. Metalloproteinase-mediated Release of Human Fas Ligand , 1995 .
[33] H. Nakano,et al. Establishment of a new human uterine cervical adenocarcinoma cell-line, siso, and its reactivity to anticancer reagents. , 1995, International Journal of Oncology.
[34] T. Colby,et al. Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving? , 1995, Annals of surgery.
[35] P. Pour,et al. Atlas of Exocrine Pancreatic Tumors , 1994, Springer Japan.
[36] J. Devière,et al. Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. , 1991, Gastroenterology.
[37] W. Steinberg. The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.
[38] D. Pleskow,et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.
[39] A. Warshaw,et al. What's New In General Surgery: Pancreatic Cancer in 1988 Possibilities and Probabilities , 1988, Annals of surgery.
[40] M. Büchler,et al. CA 19‐9 and pancreatic adenocarcinoma , 1986, Cancer.